Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature of this association was unclear. METHODS: We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case-control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. RESULTS: In nested case-control analyses from two prospective cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7). In two retrospective case-control cohorts for the evaluation of early-onset myocardial infarction, participants with CHIP had a risk of myocardial infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7). Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with coronary heart disease. CHIP carriers with these mutations also had increased coronary-artery calcification, a marker of coronary atherosclerosis burden. Hypercholesterolemia-prone mice that were engrafted with bone marrow obtained from homozygous or heterozygous Tet2 knockout mice had larger atherosclerotic lesions in the aortic root and aorta than did mice that had received control bone marrow. Analyses of macrophages from Tet2 knockout mice showed elevated expression of several chemokine and cytokine genes that contribute to atherosclerosis. CONCLUSIONS: The presence of CHIP in peripheral-blood cells was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That subjects with clonal hematopoiesis are more susceptible to develop nonhematological, most notably cardiovascular, disease”
From Aging of hematopoietic stem cells (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tet2 and Ppm1d mutant murine models have demonstrated an increased inflammatory signature in mutant macrophages, with heightened inflammatory cytokine production upon pro-inflammatory stimulation in vitro [31,32,69,70].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated IL-8 and IL-1β levels have been reported in patients with TET2 CH in the Pakistan Risk of Myocardial Infarction Study (PROMIS) [20,32]”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measured
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Self-citationMacrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Cited by
Items 501–600 of 1,015
Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis
SanMiguel, J. M., Young, K., & Trowbridge, J. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.197 · Cited by 57
Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population
Zhao, K., Shen, X., Liu, H., Lin, Z., Li, J., Chen, S., Liu, F., Huang, K., Cao, J., Liu, X., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5095 · Cited by 60
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
Guan, Y., Greenberg, E. F., Hasipek, M., Shi, C., Liu, X., Kerr, C. M., Gackowski, D., Zarakowska, E., Radivoyevitch, T., Gu, X., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01220-9 · Cited by 70
Zaro, B. W., Noh, J. J., Mascetti, V. L., Demeter, J., George, B., Zukowska, M., Gulati, G. S., Sinha, R., Flynn, R. A., Banuelos, A., et al. (2020) · eLife · doi:10.7554/elife.62210 · Cited by 58
“The initiating driver mutations in HSCs on their own can lead to clonal hematopoiesis of indeterminate potential (CHIP), which predisposes an individual to these blood diseases, as well as atherosclerosis, and affects a significant percentage of aging populations (Jaiswal et al., 2017; Jaiswal et al., 2014).”
BackgroundXie, S. Z.-J., Kaufmann, K. B., Wang, W., Chan‐Seng‐Yue, M., Gan, O. I., Laurenti, E., García‐Prat, L., Takayanagi, S., Ng, S., Xu, C., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0155 · Cited by 61
Li, S. D., Ma, M., Li, H., Waluszko, A., Sidorenko, T., Schadt, E. E., Zhang, D. Y., Chen, R., & Ye, F. (2017) · Genome Medicine · doi:10.1186/s13073-017-0478-1 · Cited by 69
Atherosclerosis and multi-organ-associated pathologies
Keeter, W. C., Ma, S., Stahr, N. A., Moriarty, A. K., & Galkina, E. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00914-y · Cited by 59
“There is an important connection between the rate of CHIP and atherosclerosis as mutations in DNMT3A, TET2, ASXL1, and JAK2 strongly correlate with the incident of CVD [20, 21].”
BackgroundBroeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 63
“CH is associated with an augmented all-cause mortality risk [53, 63] and an increased risk of atherosclerotic CVD [49, 64].”
BackgroundModern Concepts in Cardiovascular Disease: Inflamm-Aging
Puspitasari, Y. M., Ministrini, S., Schwarz, L., Karch, C., Liberale, L., & Camici, G. G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.882211 · Cited by 61
Pyroptosis in cardiovascular diseases: Pumping gasdermin on the fire
Yarovinsky, T. O., Su, M., Chen, C., Xiang, Y., Tang, W. H., & Hwa, J. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101809 · Cited by 61
Kattih, B., Shirvani, A., Klement, P., Garrido, A. M., Gabdoulline, R. R., Liebich, A., Brandes, M., Chaturvedi, A., Seeger, T., Thol, F. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01043-x · Cited by 60
“In addition, an IDH1 mutation in AML was associated with a higher percentage of CAD at diagnosis of AML in an unweighted analysis.”
InfluentialPatnaik, M. M., & Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26090 · Cited by 62
“CHIP commonly involves epigenetic regulator genes (75%; DNMT3A, TET2 and ASXL1), with mutations involving splicing genes such as SF3B1 and SRSF2 being infrequent (<5%).(98,99)”
BackgroundSex Differences and Regulatory Actions of Estrogen in Cardiovascular System
Ueda, K., Fukuma, N., Adachi, Y., Numata, G., Tokiwa, H., Toyoda, M., Otani, A., Hashimoto, M., Liu, P., & Takimoto, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738218 · Cited by 61
Cardiovascular disease and the biology of aging
Moturi, S., Ghosh-Choudhary, S. K., & Finkel, T. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.04.005 · Cited by 56
Xia, H., Shen, H., Cha, W., & Lu, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.632318 · Cited by 61
Impact of Acute and Chronic Psychosocial Stress on Vascular Inflammation
Hinterdobler, J., Schunkert, H., Kessler, T., & Sager, H. B. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0153 · Cited by 58
“Clonal hematopoiesis, the process in which increasing numbers of white blood cells derive from one single clone due to specific somatic mutations in hematopoietic stem cells (64), has recently been identified as a pathophysiological mechanism that links aging with atherosclerosis (65).”
BackgroundKimishima, Y., Misaka, T., Yokokawa, T., Wada, K., Ueda, K., Sugimoto, K., Minakawa, K., Nakazato, K., Ishida, T., Oshima, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26435-0 · Cited by 59
Epigenetic regulation of innate immune dynamics during inflammation
Caldwell, B. A., & Li, L. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae026 · Cited by 62
Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
Corces, M. R., Chang, H. Y., & Majeti, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00263 · Cited by 59
“9-fold higher risk of coronary heart disease, potentially due to an increased secretion of several cytokines and chemokines from mutant hematopoietic cells that contribute to atherosclerosis (52, 53).”
BackgroundTET2 : A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis
Liu, Y., Peng, W., Qu, K., Lin, X., Zeng, Z., Chen, J., Wei, D., & Zuo, W. (2018) · DNA and Cell Biology · doi:10.1089/dna.2017.4118 · Cited by 64
“Moreover, the LDLR-/- mice model, which was transplanted with bone morrow obtained from TET2+/- or TET2-/- mice, had larger atherosclerotic lesions in the aortic root and aorta than did mice that had received control bone marrow ( Jaiswal et al., 2014, 2017).”
BackgroundMethodPlasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation
Tall, A. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.004 · Cited by 60
Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies
Biersmith, M. A., Tong, M., Guha, A., Simonetti, O. P., & Addison, D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013755 · Cited by 57
“Though a mechanistic link between CHIP and cardiac mortality has yet to be definitively established, it is plausible that CHIP alleles confer cardiovascular risk via atherosclerosis mechanisms.(83,84) The optimal management strategies require further investigation.”
BackgroundJacob, S. L., Davis, A. A., Gerratana, L., Velimirovic, M., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1566 · Cited by 58
Somatic Mutations in Cardiovascular Disease
Heimlich, J. B., & Bick, A. G. (2022) · Circulation Research · doi:10.1161/circresaha.121.319809 · Cited by 59
Self-citationCardiac Complications in the Adult Bone Marrow Transplant Patient
Tuzovic, M., Mead, M. D., Young, P. A., Schiller, G. J., & Yang, E. H. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0774-6 · Cited by 56
Segura-Díaz, A., Stuckey, R., Florido, Y., González-Martín, J. M., López-Rodríguez, J. F., Sánchez-Sosa, S., González-Pérez, E., Perdomo, M. N. S., Perera, M. D. M., de la Iglesia, S., et al. (2020) · Cancers · doi:10.3390/cancers12040934 · Cited by 59
“9-fold higher risk of developing coronary disease and a 4-fold higher risk of myocardial infarction [12].”
BackgroundResultFebbraio, M., Roy, C. B., & Levin, L. (2021) · International Dental Journal · doi:10.1016/j.identj.2021.07.006 · Cited by 66
Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?
Ljungström, V., Mattisson, J., Halvardson, J., Pandzic, T., Davies, H., Rychlicka-Buniowska, E., Danielsson, M., Lacaze, P. A., Cavelier, L. B., Dumanski, J. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01456-2 · Cited by 55
Inflammation unites diverse acute and chronic diseases
Libby, P., Smith, R. D., Rubin, E. J., Glassberg, M. K., Farkouh, M. E., & Rosenson, R. S. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14280 · Cited by 62
“49 Once again, pro-inflammatory cytokines can stimulate the production of tissue factor procoagulant by tumour cells that can elaborate tissue factor-bearing microparticles in blood that can promote venous thrombosis, a well-known complication of many types of tumours.”
Self-citationCancer and Cardiovascular Disease
Alhuneafat, L., Guha, A., Blaes, A. H., & Konety, S. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.07.001 · Cited by 67
Opoku, E., Traughber, C. A., Zhang, D. K. Y., Iacano, A. J., Khan, M. R., Han, J., Smith, J. D., & Gulshan, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.715211 · Cited by 58
“Clonal hematopoiesis increases the risk of myocardial infarction and stroke independently of traditional risk factors (Jaiswal et al., 2017; Bick et al., 2021).”
BackgroundAtrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1
Saadatagah, S., Naderian, M., Uddin, M. M., Dikilitas, O., Niroula, A., Schuermans, A., Selvin, E., Hoogeveen, R. C., Matsushita, K., Nambi, V., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0459 · Cited by 62
Self-citationClinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 57
Immunometabolism of Phagocytes and Relationships to Cardiac Repair
Zhang, S., Bories, G. F. P., Lantz, C. W., Emmons, R., Becker, A., Liu, E., Abecassis, M. M., Yvan‐Charvet, L., & Thorp, E. B. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00042 · Cited by 55
“Clonal hematopoiesis associated with Tet2deficiency has been shown to accelerate atherosclerosis in experimental mice (124, 125), whereas whole-exome sequencing of carriers of clonal hematopoiesis of indeterminate potential (CHIP) patients indicated that mutations in TET2 are associated with heightened coronary heart…”
BackgroundInhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe−/− Mice
Tang, Y., Liu, W., Wang, W., Fidler, T. P., Woods, B., Levine, R. L., Tall, A. R., & Wang, N. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06943-9 · Cited by 57
Molitor, M., Rudi, W., Garlapati, V. S., Finger, S., Schüler, R., Kossmann, S., Lagrange, J., Nguyen, T. S., Wild, J., Knopp, T., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa042 · Cited by 58
David, C., Duployez, N., Eloy, P., Belhadi, D., Chezel, J., Guern, V. L., Laouenan, C., Fenwarth, L., Rouzaud, D., Mathian, A., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac108 · Cited by 57
Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies
Marshall, C. H., Gondek, L. P., Luo, J., & Antonarakis, E. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0985 · Cited by 58
Uddin, M. M., Saadatagah, S., Niroula, A., Yu, B., Hornsby, W., Ganesh, S., Lannery, K., Schuermans, A., Honigberg, M. C., Bick, A. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52302-9 · Cited by 64
“Consistent with previous studies 3,6 , we showed that the prevalence of CHIP increases with advancing age.”
InfluentialSelf-citationDiagnosis and Treatment of Polycythemia Vera: A Review
Tremblay, D. A., Kremyanskaya, M., Mascarenhas, J. O., & Hoffman, R. (2024) · JAMA · doi:10.1001/jama.2024.20377 · Cited by 65
Vilahur, G., & Fuster, V. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae776 · Cited by 62
Self-citationAging, hematopoiesis, and the myelodysplastic syndromes
Chung, S. S., & Park, C. Y. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009852 · Cited by 58
Franzini, A., Pomicter, A. D., Yan, D., Khorashad, J. S., Tantravahi, S. K., Than, H., Ahmann, J. M., O’Hare, T., & Deininger, M. W. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000585 · Cited by 63
“TET2 is the most commonly mutated CHIP gene and Tet2-deficient monocytes promote atherosclerosis in low-density lipoprotein receptor–deficient mice.(51,52) Liu and colleagues(53) used the Multiethnic Study of Atherosclerosis (MESA) cohort to establish”
BackgroundResultTranslating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 55
“While SF3B1 mutations in MDS have been associated with a favorable prognosis, U2AF1 and SRSF2 mutations are enriched in high-risk MDS and AML and confer an adverse prognosis (Thol et al. 2012; Bejar et al. 2015; Ohgami et al. 2015).”
BackgroundInfluentialUsova, E., Alieva, A. S., Yakovlev, A. N., Алиева, М. С., Prokhorikhin, A. A., Конради, А. О., Shlyakhto, E. V., Magni, P., Catapano, A. L., & Baragetti, A. (2021) · Biomolecules · doi:10.3390/biom11111597 · Cited by 58
“Telomere length dynamics thus mirrors the stem cell turnover and hematopoiesis simultaneously [50] and it is therefore plausible that accelerated LTL might reflect an aberrant clonal somatic hematopoietic expansion in atherosclerosis [51].”
BackgroundEmerging Roles of Inflammasomes in Cardiovascular Diseases
Liao, Y., Liu, K., & Zhu, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834289 · Cited by 61
“Clonal hematopoiesis, which is very common among the elderly, increases the risk of MI and stroke independent of traditional risk factors, among which the Jak2 (Jak2) mutations pose the greatest risk of premature coronary heart disease (89, 90).”
BackgroundMyelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
Hochman, M. J., & Dezern, A. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00138-7 · Cited by 58
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 58
Zhang, L., Xia, C., Yang, Y., Sun, F., Zhang, Y., Wang, H., Liu, R., & Yuan, M. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01298-8 · Cited by 56
“DNA demethylating enzyme TET2 represses the upregulation of pro-inflammatory cytokines, chemokine, and inflammasome activation, thus preventing atherosclerosis [59, 60].”
BackgroundClonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target
Schuermans, A., & Honigberg, M. C. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01148-9 · Cited by 59
“Despite initial reports suggesting strong associations of CHIP with incident CVD and subsequent work confirming these observations 40–42 , other studies have challenged the notion that CHIP is strongly linked with atherosclerotic CVDs. Analyses from the past 5 years of large cohorts with…”
InfluentialTherapeutic Genome Editing in Cardiovascular Diseases
German, D. M., Mitalipov, S. M., Mishra, A., & Kaul, S. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.004 · Cited by 61
“Its prevalence increases with age, and it is associated with increased risk for atherosclerotic cardiovascular disease, stroke, and death (28).”
BackgroundProceedings From the Global Cardio-Oncology Summit
Lenihan, D. J., Fradley, M. G., Dent, S. F., Brezden‐Masley, C., Carver, J. R., Filho, R. K., Neilan, T. G., Blaes, A. H., Melloni, C., Herrmann, J., et al. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.007 · Cited by 56
“Somatic mutations in blood and bone marrow cells are associated with both an increased risk of both hematologic malignancies and atherosclerotic vascular disease (85).”
BackgroundRibezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0350-3 · Cited by 51
Self-citationThe IL-1 Family and Its Role in Atherosclerosis
González, L., Rivera, K., Andía, M. E., & Martínez-Rodríguez, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010017 · Cited by 54
Genetic variation across and within individuals
Yu, Z., Coorens, T. H. H., Uddin, M. M., Ardlie, K., Lennon, N. J., & Natarajan, P. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00709-x · Cited by 55
“Clinically, TET2 mutations cause atherosclerosis in both animal experiments and human studies 14,107 whereas the role of DNMT3A mutations in atherosclerosis is less clear 115 (Fig.”
BackgroundInfluentialSelf-citationThe Notch pathway: a novel therapeutic target for cardiovascular diseases?
Aquila, G., Kostina, A. S., Sega, F. V. D., Shlyakhto, E. V., Kostareva, A. A., Marracino, L., Ferrari, R., Rizzo, P., & Malashicheva, A. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1641198 · Cited by 52
“ping between these deadly diseases is the discovery that mutations in hematopoietic blood cells, known to increase the risk of hematological malignancies, are also associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice [159].”
BackgroundSoerensen, J. F., Aggerholm, A., Kerndrup, G. B., Hansen, M. H., Ewald, I. K. L., Bill, M., Ebbesen, L. H., Rosenberg, C. A., Hokland, P., Ludvigsen, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001157 · Cited by 51
“CH has been shown to increase all-cause mortality, atherosclerosis, and the risk of developing de novo hematologic neoplasms, as well as tMN.(11-16) Moreover, in patients with CH, highdose conditioning regimens as part of treatment with ASCT have been shown to provide a proliferative advantage for mutated cell clones.”
BackgroundPotential epigenetic therapeutics for atherosclerosis treatment
Nicorescu, I., Dallinga‐Thie, G. M., de Winther, M. P. J., Stroes, E. S. G., & Bahjat, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.10.006 · Cited by 57
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
Bader, M. S., & Meyer, S. C. (2022) · Pharmaceuticals · doi:10.3390/ph15020160 · Cited by 55
“Prevalence significantly depends on the applied method and its sensitivity to detect variant allele frequencies and may therefore be higher [94].”
BackgroundHow I diagnose and treat chronic myelomonocytic leukemia
Patnaik, M. M. (2022) · Haematologica · doi:10.3324/haematol.2021.279500 · Cited by 55
Fidler, T. P., Dunbar, A. J., Kim, E., Hardaway, B., Pauli, J., Xue, C., Abramowicz, S., Xiao, T., O’Connor, K., Sachs, N., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00405-9 · Cited by 53
Heimlich, J. B., Bhat, P., Parker, A. C., Jenkins, M. T., Vlasschaert, C., Ulloa, J., Van Amburg, J. C., Potts, C. R., Olson, S., Silver, A. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011445 · Cited by 42
Self-citationCancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges
Das, D. K., Asher, A., & Ghosh, A. K. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0644-3 · Cited by 50
Clonal hematopoiesis, aging, and cardiovascular diseases
Pardali, E., Dimmeler, S., Zeiher, A. M., & Rieger, M. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.006 · Cited by 52
Clonal hematopoiesis and its emerging effects on cellular therapies
Bonin, M. V., Jambor, H. K., Teipel, R., Stölzel, F., Thiede, C., Damm, F., Kroschinsky, F., Schetelig, J., Chavakis, T., & Bornhäuser, M. (2021) · Leukemia · doi:10.1038/s41375-021-01337-8 · Cited by 60
“Assuming that the detection of somatic mutations in the autologous graft simply reflects the presence of CH, the increase in myeloid neoplasms and CVD-associated mortality, when compared to non-CH patients, merely confirms the known risk profile.”
BackgroundInfluentialAge-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
Weeks, L. D., Marinac, C. R., Redd, R., Abel, G., Lin, A., Agrawal, M., Stone, R. M., Schrag, D., & Ebert, B. L. (2022) · Blood · doi:10.1182/blood.2021014418 · Cited by 50
“Increasing evidence associates clonal hematopoiesis with systemic inflammation and polymorphic clinical manifestations including cardiovascular diseases.(4-6) Similarly, cardiovascular(7,8) and inflammatory diseases(9-11) have been observed in MDS and CMML, and chronic inflammatory stimuli have been implicated in the…”
BackgroundSelf-citationTelomeres as Therapeutic Targets in Heart Disease
Yeh, J.-K., Lin, M.-H., & Wang, C.-Y. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.009 · Cited by 49
“, diabetes, hypertension, and dyslipidemia) (79).”
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Tjota, M. Y., Segal, J. P., & Wang, P. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad091 · Cited by 53
Heart failure promotes multimorbidity through innate immune memory
Nakayama, Y., Fujiu, K., Oshima, T., Matsuda, J., Sugita, J., Matsubara, T. J., Liu, Y., Goto, K., Kani, K., Uchida, R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade3814 · Cited by 54
“Recent studies have shown that clonal hematopoiesis in the elderly is strongly associated with higher risks of cardiovascular disease ( 25 , 41 ).”
BackgroundUnleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Ellegast, J. M., Alexe, G., Hamze, A., Lin, S., Uckelmann, H. J., Rauch, P. J., Pimkin, M., Ross, L. S., Dharia, N. V., Robichaud, A. L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0956 · Cited by 53
“In the context of CHIP, TET2 mutations increase the risk of subsequent development of a hematologic malignancy but are also strongly associated with atherosclerotic cardiovascular disease and inflammation (14).”
Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade
Miller, P. G., Gibson, C. J., Mehta, A., Sperling, A. S., Frederick, D. T., Manos, M. P., Miao, B., Hacohen, N., Hodi, F. S., Boland, G. M., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00186 · Cited by 49
Self-citationKiss, T., Nyúl‐Tóth, Á., Gulej, R., Tarantini, S., Csípő, T., Mukli, P., Ungvari, A., Balasubramanian, P., Yabluchanskiy, A., Benyó, Z., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00519-1 · Cited by 50
Mechanisms involved in hematopoietic stem cell aging
Fujino, T., Asada, S., Goyama, S., & Kitamura, T. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04356-5 · Cited by 56
“Notably, mutations observed in CHIP are similar to those in myeloid neoplasms and individuals with CHIP are at increased risk for hematological malignancies and cardiovascular diseases [7, 9].”
BackgroundCancer therapy's impact on lipid metabolism: Mechanisms and future avenues
Bhatnagar, R., Dixit, N. M., Yang, E. H., & Sallam, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.925816 · Cited by 52
“The same study evaluated the effects of CHIP mutations on atherosclerosis in mice and found that mice engrafted with bone marrow obtained from TET2 knockout donors had larger atherosclerotic lesions in the aorta and aortic root than mice engrafted with control bone marrow (139).”
BackgroundThe roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies
Zhang, H., Liesveld, J. L., Calvi, L. M., Lipe, B. C., Xing, L., Becker, M. W., Schwarz, E. M., & Yeh, S.-C. A. (2023) · Bone Research · doi:10.1038/s41413-023-00249-w · Cited by 54
Anemia in older adults as a geriatric syndrome: A review
Katsumi, A., Abe, A., Tamura, S., & Matsushita, T. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14183 · Cited by 60
Noh, J.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179615 · Cited by 53
Wu, Q., Zhang, W., Lu, Y., Li, H., Yang, Y., Geng, F., Liu, J., Li, L., Pan, Y., & Li, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111558 · Cited by 47
Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal Dynamics
Mack, T., Vlasschaert, C., von Beck, K., Silver, A. J., Heimlich, J. B., Poisner, H. M., Condon, H. R., Ulloa, J., Sochacki, A. L., Spaulding, T. P., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.03.007 · Cited by 50
“The co-occurrence of driver genes was signi fi cantly different than was expected by random chance while controlling for driver-gene prevalence in the cohort ( c 2 Z 322.03, P Z 8.73 (cid:2) 10 (cid:6) 11 ).”
InfluentialSelf-citationMarston, N., Pirruccello, J. P., Melloni, G. E. M., Kamanu, F., Bonaca, M. P., Giugliano, R. P., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Steg, P. G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03188-z · Cited by 51
“CHIP has been associated with increased risk of cardiovascular (CV) disease, prompting interest in CHIP for clinical trial enrichment and as a drug target 2–6 .”
Self-citationClonal Hematopoiesis and Its Impact on Cardiovascular Disease
Sano, S., Wang, Y., & Walsh, K. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0871 · Cited by 47
Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis
Magaz, M., Álvarez‐Larrán, A., Colomer, D., López‐Guerra, M., García‐Criado, Á., Gabriel Mezzano, P., Belmonte, E., Olivas, P., Soy, G., Cervantes, F., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.045 · Cited by 49
Debureaux, P.-É., Cassinat, B., Soret‐Dulphy, J., Mora, B., Verger, E., Maslah, N., Plessier, A., Rautou, P., Ollivier‐Hourmand, I., de Lédinghen, V., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002414 · Cited by 47
“Age at diagnosis, mean (range), y 42 (17-73) 47 (7-76) .”
InfluentialRotz, S. J., Ryan, T. D., & Hayek, S. S. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02344-9 · Cited by 49
Inflammation and myeloid malignancy: quenching the flame
Stubbins, R. J., Platzbecker, U., & Karsan, A. (2022) · Blood · doi:10.1182/blood.2021015162 · Cited by 49
PET/MR imaging of inflammation in atherosclerosis
Senders, M. L., Calcagno, C., Tawakol, A. A., Nahrendorf, M., Mulder, W. J. M., & Fayad, Z. A. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00970-7 · Cited by 46
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment
d’Aiello, A., Filomia, S., Brecciaroli, M., Sanna, T., Pedicino, D., & Liuzzo, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01241-3 · Cited by 52
“Additionally, clonal hematopoiesis of indeterminate potential (CHIP), may be involved in this complex scenario and has been proposed as a cardiovascular disease (CVD) risk factor [18, 19].”
BackgroundGrimm, J., Bill, M., Jentzsch, M., Beinicke, S., Häntschel, J., Goldmann, K., Schulz, J. C., Cross, M. A., Franke, G., Behre, G., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0413-0 · Cited by 49
Clonal hematopoiesis: Pre-cancer PLUS
Silver, A. J., & Jaiswal, S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.003 · Cited by 51
“Of themutations occurring in known driver genes during normal aging, roughly 80% of mutations in CH occur in genes that are epigenetic regulators or involved with regulation of RNA splicing ( Jan, Ebert, & Jaiswal, 2017).”
BackgroundSelf-citationJiang, D., Sun, M., You, L., Lü, K., Gao, L., Hu, C., Wu, S., Chang, G., Tao, H., & Zhang, D. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.021 · Cited by 46
Somatic Variants: New Kids on the Block in Human Immunogenetics
Horebeek, L. V., Dubois, B., & Goris, A. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.09.005 · Cited by 48
Distinctive patterns of inflammation across the heart failure syndrome
Schiattarella, G. G., Sequeira, V., & Ameri, P. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09949-5 · Cited by 54
Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All
Lomas, O., Mouhieddine, T. H., Tahri, S., & Ghobrial, I. M. (2020) · Cancers · doi:10.3390/cancers12061554 · Cited by 48
“More recently, the phenomenon of clonal hematopoiesis of indeterminate potential (CHIP) has been implicated mechanistically in atherosclerotic arterial disease [92].”
BackgroundKiefer, K. C., Cremer, S., Pardali, E., Aßmus, B., Abou‐El‐Ardat, K., Kirschbaum, K., Dorsheimer, L., Rasper, T., Berkowitsch, A., Serve, H. L., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13297 · Cited by 49
Diverse Epigenetic Regulations of Macrophages in Atherosclerosis
Yang, H., Sun, Y., Li, Q., Jin, F., & Dai, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.868788 · Cited by 54
“DNMT3A and TET2 represent the most commonly mutated genes in patients with coronary heart disease carrying clonal hematopoiesis of indeterminate potential (CHIP) (45).”
BackgroundCalcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
Li, M., Binder, M., Lasho, T. L., Ferrer, A., Gangat, N., Al‐Kali, A., Mangaonkar, A. A., Elliott, M., Litzow, M. R., Hogan, W. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003976 · Cited by 45
“consensus criteria are pending.(7,8) In our study we further classified CCUS patients into CCUS-HighVAF based on a dominant mutational VAF of $20%.”
Cimmino, G., Muscoli, S., Rosa, S. D., Cesaro, A., Perrone, M. A., Selvaggio, S., Selvaggio, G., Aimo, A., Pedrinelli, R., Mercuro, G., et al. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001450 · Cited by 48
Cell-intrinsic effects of clonal hematopoiesis in heart failure
Abplanalp, W. T., Schuhmacher, B., Cremer, S., Merten, M., Shumliakivska, M., Mačinković, I., Zeiher, A. M., John, D., & Dimmeler, S. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00322-x · Cited by 60
Wang, J., Shao, F., Yu, Q., Ye, L., Wusiman, D., Wu, R., Tuo, Z., Wang, Z., Li, D., Cho, W. C. S., et al. (2025) · Research · doi:10.34133/research.0612 · Cited by 72
“DNMT3A and TET2, pivotal in methylation and demethylation, are often mutated in conditions predisposing individuals to hematologic cancers and heart disease [ 172 ].”
Metadata
- Authors
- Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberg, D., Libby, P., Kathiresan, S., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- ORCID
- Jaiswal, Siddhartha
- Natarajan, Pradeep
- Silver, Alexander J.
- Gibson, Christopher J.
- Bick, Alexander G.
- McConkey, Marie
- Gupta, Namrata
- Gabriel, Stacey
- Ardissino, Diego
- Baber, Usman
- Mehran, Roxana
- Danesh, John
- Saleheen, Danish
- Melander, Olle
- Sukhova, Galina K.
- Neuberg, Donna
- Libby, Peter
- Kathiresan, Sekar
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-13
- Volume
- 377
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6717509
- OpenAlex
- W2628145035
- Cited by
- 2,683
- References
- 37
- Citations by year
- 2026: 303 · 2025: 322 · 2024: 347 · 2023: 338 · 2022: 371 · 2021: 303 · 2020: 263 · 2019: 215 · 2018: 169 · 2017: 44
- FWCI
- 143.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL082945, R01HL080472, RC2HL101834, T32HL116324)
- National Human Genome Research Institute (U54HG003067)
- Fogarty International Center (RC1TW008485)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- clonal hematopoiesis of indeterminate potential, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, coronary artery calcification, TET2 mutation, DNMT3A, ASXL1, JAK2, somatic mutations, atherosclerosis, cytokines and chemokines, macrophages, bone marrow transplantation
- MeSH terms
- Animals, Coronary Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mutation, Risk, Case-Control Studies, Sequence Analysis, DNA, Mice, Knockout, Genetic Predisposition to Disease, Atherosclerosis, Mice, Exome, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.